Finance

Lists
Why is CNTX up 4,66%?
Dive Deeper
CNTX:NASDAQ
Context Therapeutics Inc
0,31 $
+4,66%
(+0,014) 1D
0,31 $
+0,13% (+0,00040)
Pre-market
Closed: 1 қаз., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CNTX...
Open
0,31 $
High
0,32 $
Low
0,30 $
Mkt. cap
28,93 млн
Avg. vol.
1,66 млн
Volume
13,08 мың
52-wk high
3,62 $
52-wk low
0,30 $
EPS
-0,48 $
Beta
1,69
Shares outstanding
91,88 млн
No. of employees
15
Open
0,31 $
High
0,32 $
Low
0,30 $
Mkt. cap
28,93 млн
Avg. vol.
1,66 млн
Volume
13,08 мың
52-wk high
3,62 $
52-wk low
0,30 $
EPS
-0,48 $
Beta
1,69
Shares outstanding
91,88 млн
No. of employees
15
News stories
From web sources and news partners
About Context Therapeutics Inc
CEO-
Employees15
Founded2015
HeadquartersФиладельфия, Пенсильвания, Америка Құрама Штаттары
SectorPharmaceutical industry
Websitecontexttherapeutics.com
Analyst ratings
Based on 6 analysts giving stock ratings to CNTX in the past 3 months
Strong buy
Buy
5
Hold
1
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for CNTX in the last 3 months.
Highest
Current 0,31 $
5,00 $ (+1 490,33%)
Average
3,20 $ (+917,81%)
Lowest
2,00 $ (+536,13%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason McCarthy
Maxim Group
Buy
Maintained
4,00 $
+1 172,3%
08/10/2026
Charles Zhu
LifeSci Capital
Hold
Downgraded
2,00 $
+536,1%
08/08/2026
Silvan Turkcan
Citizens JMP
Buy
Maintained
3,00 $
+854,2%
08/06/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
08/06/2026
Boris Peaker
JonesTrading
Buy
Reiterated
2,00 $
+536,1%
08/06/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
5,00 $
+1 490,3%
08/06/2026
Biren Amin
Piper Sandler
Buy
Maintained
7,00 $
+2 126,5%
06/02/2026
Paul Jeng
Guggenheim
Buy
Maintained
5,00 $
+1 490,3%
05/06/2026
Soumit Roy
JonesTrading
Buy
Maintained
7,00 $
+2 126,5%
04/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
8,72 млн
11,84 млн
7,02 млн
12,53 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,89 млн
1,96 млн
2,33 млн
2,44 млн
Operating expense
10,61 млн
13,80 млн
9,34 млн
14,97 млн
Total operating expenses
10,61 млн
13,80 млн
9,34 млн
14,97 млн
Operating income
-10,61 млн
-13,80 млн
-9,34 млн
-14,97 млн
Other non operating income
83,47 мың
96,56 мың
-
-9,60 мың
EBT including unusual items
-9,69 млн
-13,03 млн
-8,68 млн
-14,56 млн
EBT excluding unusual items
-9,69 млн
-13,03 млн
-8,68 млн
-14,56 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-9,69 млн
-13,03 млн
-8,68 млн
-14,56 млн
Net profit margin
-
-
-
-
Earnings per share
-0,10
-0,14
-0,09
-0,15
Interest and investment income
833,77 м.
682,48 м.
520,14 м.
418,66 м.
Interest expense
-
-
-
-
Net interest expenses
833,77 м.
682,48 м.
520,14 м.
418,66 м.
Depreciation and amortization charges
-
-
-
-
EBITDA
-10,61 млн
-13,80 млн
-9,34 млн
-14,96 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google қолданбалары